B. Pitcher

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

D. Berry, C. Perou, E. Winer, 2014 .

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).

H. Cohen, E. Winer, C. Hudis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL

D. Scott, J. Leonard, A. Mottok, 2017 .

A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901 ✰

Gretchen, C. Hudis, W. Barry, 2014 .

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.

J. Leonard, B. Cheson, Sin-Ho Jung, 2014 .

A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.

H. Cohen, E. Winer, C. Hudis, 2013, Journal of geriatric oncology.

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

M. Czuczman, J. Leonard, B. Cheson, 2015 .

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.